GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Elbit Imaging Ltd (XTAE:EMITF-M) » Definitions » Valuation Rank

Elbit Imaging (XTAE:EMITF-M) Valuation Rank


View and export this data going back to 1986. Start your Free Trial

What is Elbit Imaging Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.


Elbit Imaging Valuation Rank Related Terms

Thank you for viewing the detailed overview of Elbit Imaging's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Elbit Imaging (XTAE:EMITF-M) Business Description

Traded in Other Exchanges
Address
3 Shimshon Street, Olympia A Tower, Petach Tikva, ISR, 4900102
Elbit Imaging Ltd is an Israel based company. The business activity of the group is operated through two segments including Medical industries and devices, and Plots in India. Geographically the business presence is in the region of America, Europe, and ROW. The company derives maximum revenue from the Medical industries and devices segment which operates in the field of life science that includes development, production, and marketing of treatment-oriented medical systems, and for certain cancer diseases in the America region.